High-density lipoprotein/apolipoprotein A-I infusion therapy.
Strategies to decrease the progression and burden of atherosclerosis by capitalizing on the protective effect of high-density lipoprotein (HDL) and/or apolipoprotein A1 (apoA-I) levels remain active. Although efforts to raise HDL through the administration of oral agents are still being pursued, the disappointing results demonstrated with torcetrapib, an agent that elevated serum HDL and apoA-I levels through the inhibition of cholesterol ester transfer protein, have raised questions regarding this approach. An alternate strategy that consists of short-term infusions of reconstituted HDL or apoA-I is currently under evaluation. Several infusion compounds have been evaluated in clinical trials that utilize cardiovascular imaging technologies and biomarkers to assess potential clinical efficacy. Although these compounds are still in early-stage development, the results of these trials have supported the viability of this line of investigation. This review addresses the potential of HDL and/or apoA-I infusions as a possible therapeutic strategy for the treatment of coronary artery disease.
Tardif
Jean-Claude
JC
Department of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada. claude.tardif@icm-mhi.org
Heinonen
Therese
T
Noble
Stephane
S
D016632:Apolipoprotein A-I / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000097:blood / Q000628:therapy*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007262:Infusions, Intravenous; D008075:Lipoproteins, HDL / Q000008:administration & dosage*
D016632:Apolipoprotein A-I; D008075:Lipoproteins, HDL